<DOC>
	<DOCNO>NCT00038051</DOCNO>
	<brief_summary>The goal clinical research study find high safe dose anti-CD33 immunotoxin HuM-195/rGel give patient advanced myeloid malignancy . This treatment give patient whose leukemia respond prior chemotherapy .</brief_summary>
	<brief_title>Evaluation Anti-CD-33 Immunotoxin Hum-195/rGel Patients With Advanced Myeloid Malignancies</brief_title>
	<detailed_description>Before therapy , patient ask medical history , physical exam ( measurement vital sign ) perform . A chest X-ray electrocardiogram ( ECG - test measure electrical activity heart ) perform . Blood ( 4 teaspoon ) draw routine test blood clot test . Women able become pregnant urine pregnancy test do . A test do measure amount oxygen blood place monitoring device finger . Blood ( 1 teaspoon ) take measure amount protein present diseased cell . During study period , study staff draw blood sample routine test , pharmacokinetic ( PK ) test , anti-drug antibody test . Blood ( 1 teaspoon ) drawn measure amount protein present diseased cell . A bone marrow sample also obtain treatment Study Day 28 . Patients receive four injection immunotoxin . The immunotoxin design selectively destroy myeloid leukemia cell . The injection give vein twice weekly two week . Patients evaluate twice weekly next two week . If improvement leukemia , leukemia remain stable serious side effect treatment , patient receive second course immunotoxin injection . These give twice weekly two week . Depending effectiveness leukemia side effect , patient may receive maintenance treatment . This would also consist two weekly injection give two week follow two week observation . Maintenance therapy may continue four month partial response two month complete response . This investigational study . Up 36 patient take part study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Anemia , Refractory</mesh_term>
	<mesh_term>Anemia , Refractory , Excess Blasts</mesh_term>
	<mesh_term>Immunotoxins</mesh_term>
	<criteria>1 . Patients relapse refractory acute myelogenous leukemia ( AML ) , Refractory anemia excess blast transformation ( RAEBt ) , Refractory Anemia Excess Blasts ( RAEB ) , chronic myelomonocytic leukaemia ( CMML ) fail least one previous chemotherapy course . Patients accelerate CML Ph+ myeloid blastic crisis eligible . Patients accelerate phase nonPhiladelphia chromosome + myeloproliferative disorder also eligible : P. vera , myelofibrosis essential thrombocytopenia &gt; 5 % blast blood bone marrow . 2 . Male female 18 yrs age older provide write informed consent 3 . Tumor cell must = &gt; 80 % CD33 positive flow cytometry 4 . For woman childbearing potential ( i.e . exclude postmenopausal woman , woman surgically sterilize ) , adequate birth control method must use . Acceptable birth control method limit oral contraceptive , implant , diaphragm , IUD spermicide use condom 5 . White blood count ( WBC ) count &lt; 10,000/ml AML , MDS , myeloproliferative disorder 30,000 accelerate CML 6 . No cytotoxic chemotherapy two week prior enter study 7 . No evidence residual toxic effect grade 2 high prior chemotherapy 8 . Patients proven bacterial infection eligible resolution infection ( patient afebrile , steroid ) . Patients active fungal infection eligible evidence response antifungal medication document fever exceed 38Â°C 9 . Creatinine Patients value = &lt; 1.5 time upper limit laboratory normal value 10 . Liver function Patients serum bilirubin value = &lt; 2.0 time upper limit laboratory normal value . Patients SGOT and/or SGPT level = &lt; 2.5 time upper limit laboratory normal value 11 . Cardiac function Patients cardiovascular disease &lt; New York Heart Association ( NYHA ) classification III 12 . Pulmonary function O2 saturation = &gt; 92 % without exogenous O2 administer . 13 . Neurologic function Patients normal central nervous system function well normal motor function consistent = &lt; Grade 1 toxicity . Patients peripheral sensory function damage ( neuropathy ) exceed Grade 1 toxicity Women pregnant lactating</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Chronic Myelomonocytic Leukemia</keyword>
	<keyword>CMML</keyword>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Refractory Anemia Excess Blasts</keyword>
	<keyword>RAEB-t</keyword>
	<keyword>RAEB</keyword>
	<keyword>Hum-195/rGel</keyword>
</DOC>